News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zongyi Group Invests $8.6 Million in ContraFect Corporation a U.S. Biotech



4/19/2013 1:45:16 PM

by Richard Daverman, PhD

April 19. 2013 -- The Zongyi Group of China has invested $8.6 million in ContraFect Corporation, a New York City-area biotech that is developing biotech antibiotics. ContraFect is focused on the use of monoclonal antibodies and lysins as solutions for difficult-to-treat infectious diseases. The company said the new capital – it raised $9.5 million in the round – would advance a new drug toward clinical trials. ContraFect also expects Zongyi to open doors for the company in China. More details....


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES